Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,388 total articles

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Theriva Biologics announced new tumor response, biomarker, and subgroup analyses from its VIRAGE Phase 2b clinical trial evaluating VCN-01 combined with gemcitabine/nab-paclitaxel in metastatic pancreatic cancer patients. The data, to be presented at AACR 2026, reinforce VCN-01's immune-mediated mode of action and demonstrate improved outcomes, inc…

VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) – ITS 12TH CONSECUTIVE INCREASE

VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) – ITS 12TH CONSECUTIVE INCREASE

Value Line, Inc. announced a 7.7% increase in its quarterly dividend to $0.35 per share ($1.40 annualized), reflecting its 12th consecutive annual dividend increase. The dividend is payable on May 12, 2026, to shareholders of record as of April 27, 2026. The company provides a broad range of investment research products and services, including equi…

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene Inc. presented new clinical data at AACR 2026 demonstrating that their masked anti-CTLA-4 therapy muzastotug, when combined with immunotherapies like atezolizumab and bevacizumab or pembrolizumab and fruquintinib, shows significantly improved overall response rates and manageable safety profiles in advanced hepatocellular carcinoma and micr…

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Evaxion A/S announced promising phase 2 trial data for its personalized cancer vaccine EVX-01, designed with its AI-Immunology™ platform, showing an 86% success rate in vaccine targets eliciting tumor-specific immune responses. The data, presented at the AACR Annual Meeting, reinforce the platform's capability to select relevant vaccine targets and…

PRAME-directed Cell Therapy Using Immatics’ TCR  Induces Deep and Durable Remission in Pediatric Patient  with Advanced Metastatic Nephroblastoma

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Immatics announced that a pediatric patient with advanced metastatic nephroblastoma achieved deep and durable remission following an individual experimental treatment using their PRAME-directed T-cell receptor (TCR) therapy. The treatment led to marked regression of metastases in multiple organs and ongoing remission at 6 months, highlighting the p…

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Evaxion A/S announced new data demonstrating its AI-Immunology platform's capability to identify novel endogenous retrovirus-derived antigens as targets for glioblastoma cancer vaccines. Collaborating with Duke University, the company found that integrating these ERV antigens could overcome challenges posed by glioblastoma's low mutational burden, …

Kaltura to Showcase Agentic Revenue Engagement Platform at Adobe Summit 2026, Demonstrating How Agentic AI Avatars and Content Intelligence Turn Static ABM Pages Into Real-Time Conversations

Kaltura to Showcase Agentic Revenue Engagement Platform at Adobe Summit 2026, Demonstrating How Agentic AI Avatars and Content Intelligence Turn Static ABM Pages Into Real-Time Conversations

Kaltura, Inc. premiered its Agentic Revenue Engagement platform at Adobe Summit 2026, combining its AI-powered video and avatar technology with PathFactory's content intelligence and journey orchestration. The platform enables real-time conversational experiences within Adobe Experience Manager, transforming static ABM pages into adaptive, personal…

MOZAYYX Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 20, 2026

MOZAYYX Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing April 20, 2026

MOZAYYX Acquisition Corp. revealed that beginning April 20, 2026, holders of its IPO units will be able to separately trade the Class A ordinary shares and warrants comprising the units on the NYSE under the symbols MZYX and MZYX.WS respectively. The company operates as a blank check firm aiming to acquire businesses in high-growth sectors such as …

Odysight.ai Signs Commercial Collaboration Agreement with GACI Technologies to Expand AI-Powered Predictive Maintenance into the French Aerospace and Defense Market

Odysight.ai Signs Commercial Collaboration Agreement with GACI Technologies to Expand AI-Powered Predictive Maintenance into the French Aerospace and Defense Market

Odysight.ai Inc., a U.S.-listed company specializing in AI/ML visual sensing for predictive and condition-based maintenance, has entered into a commercial collaboration agreement with French aerospace and defense firm GACI Technologies. The partnership aims to bring Odysight.ai's AI-driven predictive maintenance systems to France's advanced aerospa…

Kandal M Venture Limited Issues Guidance Projecting Improved Top and Bottom Line for Full Year Fiscal 2026

Kandal M Venture Limited Issues Guidance Projecting Improved Top and Bottom Line for Full Year Fiscal 2026

Kandal M Venture Limited, a Nasdaq-listed contract manufacturer of affordable luxury leather goods, projects improved revenue and net income for fiscal 2026 versus fiscal 2025. The company is diversifying its customer base to markets with lower tariff impact such as the UK, Japan, and other countries, and expanded manufacturing to the Philippines t…

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences announced updated preclinical results for its CGT1263 pan-KRAS inhibitor and CGT4255 ErbB2 inhibitor at the AACR Annual Meeting 2026. The data suggest improved selectivity and reduced toxicity for CGT1263, and enhanced brain penetration plus synergistic effects with HER2 ADC therapies for CGT4255. These advancements underscore th…

WEBUY GLOBAL LTD. Launches Exclusive Antarctica Expedition Cruise Under Premium Brand Altitude Travel, Achieves Over US$777,500 in First Month Total Transaction Value

WEBUY GLOBAL LTD. Launches Exclusive Antarctica Expedition Cruise Under Premium Brand Altitude Travel, Achieves Over US$777,500 in First Month Total Transaction Value

WEBUY GLOBAL LTD. announced the launch of a premium Antarctica expedition cruise under its high-end Altitude Travel brand, generating over US$777,500 in total transaction value in its first month. The exclusive chartered 15-day cruise offers immersive expedition experiences and AI-assisted personalization to attract affluent travelers, signaling st…

Myseum.AI Accepted into Advanced Micro Devices AI Developer Program

Myseum.AI Accepted into Advanced Micro Devices AI Developer Program

Myseum.AI, a privacy-first social media and AI technology company, announced its acceptance into the Advanced Micro Devices (AMD) AI Developer Program, gaining access to AMD's tools and resources to accelerate AI development. Concurrently, CEO Darin Myman was highlighted as a 'Next Super Stock' by Wall Street Reporter, reflecting investor interest …

KUSTOM ENTERTAINMENT AND CYCURION ANNOUNCE AGREEMENT ON TERMS FOR SALE OF LEGACY VIDEO SOLUTIONS SEGMENT

KUSTOM ENTERTAINMENT AND CYCURION ANNOUNCE AGREEMENT ON TERMS FOR SALE OF LEGACY VIDEO SOLUTIONS SEGMENT

Kustom Entertainment and Cycurion have reached a revised agreement for the sale of Kustom's legacy video solutions segment for $5.5 million, including cash, a secured note, performance incentives, and stock warrants. The deal supports Kustom's focus on core growth areas, while enabling Cycurion to expand its cybersecurity and AI portfolio. The tran…

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio announced upcoming presentations at the 2026 American Thoracic Society International Conference showcasing new Phase 2 data on Verekitug, their novel TSLP receptor antagonist, in treating chronic rhinosinusitis with nasal polyps and comorbid asthma. The data highlights clinical effects and biomarker impacts, underscoring its potential …